Memphis Pharmaceuticals & Chemical Industries (EGX: MPCI)
Egypt
· Delayed Price · Currency is EGP 57.61
+0.01 (0.02%)
At close: Nov 21, 2024
MPCI Income Statement
Financials in millions EGP. Fiscal year is July - June.
Millions EGP. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Operating Revenue | 1,089 | 871.91 | 663.83 | 551.26 | 518.11 | 488.41 | Upgrade
|
| Revenue | 1,089 | 871.91 | 663.83 | 551.26 | 518.11 | 488.41 | Upgrade
|
| Revenue Growth (YoY) | 56.42% | 31.34% | 20.42% | 6.40% | 6.08% | 34.52% | Upgrade
|
| Cost of Revenue | 656.29 | 573.41 | 450.88 | 401.87 | 353.14 | 396.25 | Upgrade
|
| Gross Profit | 432.62 | 298.49 | 212.95 | 149.39 | 164.98 | 92.16 | Upgrade
|
| Selling, General & Admin | 91.24 | 87.87 | 77.41 | 71.8 | 75.98 | 24.44 | Upgrade
|
| Other Operating Expenses | 32.26 | 25.15 | 39.65 | 8.55 | 54.86 | 56.12 | Upgrade
|
| Operating Expenses | 123.5 | 113.02 | 117.06 | 80.35 | 130.84 | 80.55 | Upgrade
|
| Operating Income | 309.12 | 185.47 | 95.89 | 69.04 | 34.13 | 11.61 | Upgrade
|
| Interest Expense | -14.26 | -14.26 | - | - | - | - | Upgrade
|
| Interest & Investment Income | 82.66 | 55.65 | 11.13 | 7.28 | 5.41 | 5.98 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | 0.67 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 1.42 | 2.65 | 2.96 | 1.34 | 2.11 | -0 | Upgrade
|
| EBT Excluding Unusual Items | 378.95 | 229.52 | 109.98 | 78.32 | 41.65 | 17.59 | Upgrade
|
| Other Unusual Items | - | - | - | - | - | -1.79 | Upgrade
|
| Pretax Income | 378.95 | 229.52 | 109.98 | 78.32 | 41.65 | 15.8 | Upgrade
|
| Income Tax Expense | 71.4 | 38.06 | 19.55 | 4.23 | -0.15 | -1.61 | Upgrade
|
| Net Income | 307.55 | 191.46 | 90.44 | 74.09 | 41.81 | 17.41 | Upgrade
|
| Net Income to Common | 307.55 | 191.46 | 90.44 | 74.09 | 41.81 | 17.41 | Upgrade
|
| Net Income Growth | 199.94% | 111.70% | 22.07% | 77.22% | 140.14% | - | Upgrade
|
| Shares Outstanding (Basic) | - | 6 | 6 | 6 | - | 6 | Upgrade
|
| Shares Outstanding (Diluted) | - | 6 | 6 | 6 | - | 6 | Upgrade
|
| EPS (Basic) | - | 34.04 | 16.08 | 13.17 | - | 3.09 | Upgrade
|
| EPS (Diluted) | - | 34.04 | 16.08 | 13.17 | - | 3.09 | Upgrade
|
| EPS Growth | - | 111.70% | 22.07% | - | - | - | Upgrade
|
| Free Cash Flow | 28.99 | 158.83 | 46.49 | 23.55 | 1.4 | -3.98 | Upgrade
|
| Free Cash Flow Per Share | - | 28.24 | 8.26 | 4.19 | - | -0.71 | Upgrade
|
| Dividend Per Share | 4.000 | 4.000 | 2.000 | - | - | - | Upgrade
|
| Dividend Growth | 100.00% | 100.00% | - | - | - | - | Upgrade
|
| Gross Margin | 39.73% | 34.23% | 32.08% | 27.10% | 31.84% | 18.87% | Upgrade
|
| Operating Margin | 28.39% | 21.27% | 14.45% | 12.52% | 6.59% | 2.38% | Upgrade
|
| Profit Margin | 28.24% | 21.96% | 13.62% | 13.44% | 8.07% | 3.56% | Upgrade
|
| Free Cash Flow Margin | 2.66% | 18.22% | 7.00% | 4.27% | 0.27% | -0.82% | Upgrade
|
| EBITDA | 322.38 | 197.65 | 103.65 | 76.68 | 43.88 | 21.29 | Upgrade
|
| EBITDA Margin | 29.61% | 22.67% | 15.61% | 13.91% | 8.47% | 4.36% | Upgrade
|
| D&A For EBITDA | 13.26 | 12.18 | 7.75 | 7.64 | 9.74 | 9.68 | Upgrade
|
| EBIT | 309.12 | 185.47 | 95.89 | 69.04 | 34.13 | 11.61 | Upgrade
|
| EBIT Margin | 28.39% | 21.27% | 14.45% | 12.52% | 6.59% | 2.38% | Upgrade
|
| Effective Tax Rate | 18.84% | 16.58% | 17.77% | 5.40% | - | - | Upgrade
|
| Revenue as Reported | - | - | - | - | - | 490.1 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.